search
Back to results

Transforaminal Epidural Steroid Injection With Pulsed Radiofrequency for Chronic Lumbosacral Radicular Pain Management

Primary Purpose

Radicular; Neuropathic, Lumbar, Lumbosacral, Low Back Pain, Back Pain With Radiation

Status
Unknown status
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Celestone
pulsed radiofrequency treatment
Control
Sponsored by
Sheba Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Radicular; Neuropathic, Lumbar, Lumbosacral focused on measuring lumbar dorsal root ganglion, transforaminal epidural steroid injection, chronic lumbosacral radicular pain, pulsed radiofrequency treatment, betamethasone, dorsal root ganglion

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • men and women
  • age ≥18 years old,
  • pain intensity≥4 out of 10 on the numerical rating scale (NRS),
  • chronic lumbosacral radicular pain lasting ≥12 weeks,
  • dominant leg pain with less intense back pain,
  • the previous failure of conservative management such as physiotherapy, exercise therapy, or analgesic medications.
  • segmental pain of a radicular nature originating from the lumbar segments and with a shooting or lancinating quality corresponding to a dermatome suggestive of the involved nerve root.
  • availability of computed tomography/magnetic resonance imaging findings of pathology concordant with the side and level of their clinical features.

Exclusion Criteria:

  • patient refusal to participate in the study,
  • age <18 years,
  • pregnant or nursing
  • pain <4-points on NRS,
  • acute pain of onset lasting<12 weeks,
  • progressive motor weakness in the affected leg,
  • allergies to local anesthetics, contrast dyes or steroids
  • significant anatomic deformity (either congenital or acquired) making it difficult to access the foramen as evidenced by computed tomography/magnetic resonance imaging
  • presence of cancer accounting for back pain
  • patients with platelet dysfunction, bleeding disorder or continuing anticoagulant treatment
  • steroid injection within the previous 12 weeks,
  • systemic infection,
  • injection site infection,
  • unstable medical or psychiatric condition

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Other

    Arm Label

    Celestone

    Control

    Arm Description

    all patients of the experimental Celestone group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of Celestone® Chronodose® around each dorsal root ganglion immediately after the radiofrequency treatment has been performed.

    all patients of the control group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of normal saline around each dorsal root ganglion immediately after the radiofrequency treatment will be performed.

    Outcomes

    Primary Outcome Measures

    pain scores
    Changes in pain scores, as reported by the patients via the NRS scores, will be analyzed before the procedure and at 1, 2 and 3 months after the treatment
    quality of life and activities of daily living
    The potential changes in quality of life and activities of daily living will be measured by validated Roland Disability Questionnaire or Oswestry Disability Index scores

    Secondary Outcome Measures

    adverse events

    Full Information

    First Posted
    October 6, 2016
    Last Updated
    October 13, 2016
    Sponsor
    Sheba Medical Center
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02930057
    Brief Title
    Transforaminal Epidural Steroid Injection With Pulsed Radiofrequency for Chronic Lumbosacral Radicular Pain Management
    Official Title
    Transforaminal Epidural Steroid Injection in Conjunction With Pulsed Radiofrequency Treatment of the Lumbar Dorsal Root Ganglion for the Management of Chronic Lumbosacral Radicular Pain: a Randomized, Double-blind Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    October 2016
    Overall Recruitment Status
    Unknown status
    Study Start Date
    October 2016 (undefined)
    Primary Completion Date
    October 2017 (Anticipated)
    Study Completion Date
    October 2018 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Sheba Medical Center

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The purpose of this study is to examine the potential changes in levels of pain, quality of life (QoL) and activities of daily living (ADL) observed when transforaminal epidural steroid injection is administered in conjunction with pulsed radiofrequency treatment of the lumbar dorsal root ganglion during the initial 3 months follow-up period. Safety (monitoring side effects) of the treatment is determined. The study hypothesis is that the application of transforaminal epidural steroid injection (TFESI) in conjunction with pulsed radiofrequency treatment (PRF) treatment of the lumbar dorsal root ganglion would increase the treatment response of PRF and thereby provide a measurable difference in the pain scores, quality of life and activities of daily living for the patients suffering from chronic lumbosacral radicular pain.
    Detailed Description
    The study sample: 120 (one hundred and twenty) patients diagnosed with chronic lumbosacral radicular pain were elected by their pain specialists to undergo pulsed radiofrequency treatment adjacent to lumbosacral dorsal root ganglion(s). A patient with radicular pain affecting more than one segment on one side will be treated for all the involved segments with the same technique and this will be considered a single intervention for the study. 60 (sixty) patients (the experimental Celestone group) undergoing pulsed radiofrequency treatment will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of Celestone Chronodose around each dorsal root ganglion immediately after the radiofrequency treatment has been performed. 60 (sixty) patients (the control group) undergoing pulsed radiofrequency treatment will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of normal saline around each dorsal root ganglion immediately after the radiofrequency treatment will be performed. Randomization and blinding: Patients will be randomly assigned to the Celestone group (N = 60) or the control group (N = 60). The allocation of patients into either group will be performed using a computer-generated randomization program. Each patient's randomization number will be concealed until the end of the study from both the patients and the outcome assessor, who will be an independent research coordinator at the investigators pain clinic. The patients will be explained that they will not know which medicine they will receive until the study completion. Procedure: The study will take place in the Chaim Sheba TelHashomer Medical Center, Ramat Gan, Israel. Participants will be recruited from the hospital's Pain Management outpatient clinic from the patients eligible for the procedure involving pulsed radiofrequency of the lumbosacral dorsal root ganglion. After receiving the hospital's Helsinki approval, the P.I. and/or other designated staff in the department will approach relevant patients (in line with the mentioned inclusion and exclusion criteria), describe the procedure, inform of the possible adverse events and collect informed consent if the patients are interested in participating. Consent will be obtained from the patient during the patient's visit when the option of RF is agreed upon and scheduled for the future. Eligible patients will not receive any financial reimbursement. It will be stressed to prospective subjects that participation in the research will have no implications on their treatment in the hospital, or the relationship with their current healthcare providers. The patients will be advised that they may unconditionally revoke their consent at any given time during participation without repercussion on future care. For the first month after the procedure, patients will be instructed not to change their previously prescribed analgesic medications. All patients will be made aware of this guideline prior to study participation. After the first month follow-up visit, the prescribed doses of any analgesics will be increased or decreased in regard to the pain intensity of the patient. Patients who will have increments in analgesic medication or who will be elected for alternative treatments will be considered treatment failure. Data collected during the experiment will be kept in a secure location and will be shredded after the project's completion. All information regarding patients treatment both inside and outside of the project will be kept in the utmost of confidentiality, respecting both legal and ethical constraints. Patients agreeing to participate in the study will come to the pre-operative room of the Pain Department at the designated time. There they will be monitored, initial intensity of the pain (0 to 10) on the numerical rating scale (NRS) will be recorded and pre-operative vital signs assessed (e.g.- blood pressure, heart rate, oxygen saturation). Each patient will complete the Roland Disability Questionnaire and the Oswestry Disability Index score. All syringes with the solutions to be injected by the transforaminal approach will be prepared prior to entering the operating room. After that the patient will enter the operating room to undergo pulsed radiofrequency treatment. The patient will sign consent for the procedure. The patient will be placed in the prone position with a pillow under the lower abdomen to provide an easy transforaminal approach. It will be forbidden to call name or the dose of any medication which will be injected during the procedure except the 1.5cc of Midazolam IV that will be given for light sedation. Fluoroscopy will be used to identify the specific site of the injections and radiofrequency in all cases. After sterile preparation of the needle insertion area, the skin will be infiltrated with 1% Lidocaine, and a 22-gauge, 4-in radiofrequency needle with a 10 mm curved active tip will be advanced under fluoroscopic guidance. Anatomic landmarks will be identified, and the needle will be positioned closely to the dorsal root ganglion under fluoroscopy guidance. The tip of the needle will be placed in the dorsal-cranial quadrant of the intervertebral foramen on the oblique image, and the tip will be positioned between one-third and halfway to the pedicle column on the antero-posterior image. If intravenous uptake will be occurred, the needle will be repositioned until intravenous uptake was absent and an epidural flow pattern was achieved. If intra-arterial, intrathecal, or intradiscal flow will be identified, the procedure was aborted. After confirmation of epidural spread (using a contrast dye) and the radiofrequency needle positioning adjacent to the appropriate dorsal root ganglion, 1 cc of normal saline will be injected to decrease electrical impedance around the radiofrequency needle. Then the stylet will be replaced by the radiofrequency probe and the probe will be connected to the radiofrequency generator. Defining the final position of the radiofrequency probe will require a sensory stimulation (50 Hz) threshold ≤0.5 V, which will create paresthesia corresponding to the existing distribution of the patient's radicular pain. Then in the two groups of patients two cycles of pulsed radiofrequency will be performed at 42°C for 120 seconds. Immediately after the radiofrequency treatment in the Celestone group the solution of 1 cc of Lidocaine 1% with 1 cc of Celestone Chronodose will be injected around each dorsal root ganglion through the radiofrequency needle. In the control group the solution of 1 cc of Lidocaine 1% with 1 cc of normal saline will be injected. All patients will be treated according to the protocol. If an emergency situation occurs or in case of unblinding, the treatment will be altered and the patients will be considered withdrawn. Such patients will proceed with conservative or interventional management without unblinding. They will also continue their structured exercise program, as other patients do. After the procedure the patient will be taken to the recovery room in the pain clinic and will be monitored for at least for 30 minutes. Vital signs will be assessed immediately post-op in the recovery room and again after 30 minutes, just prior to discharge. Requests for additional analgesia (Optalgin, etc) will be assessed. During the 30 minutes following the entry to recovery room the patients will be asked if they are experiencing any of a number of the symptoms used by the list of adverse events and their responses will noted in their records. All the patients will be warned of potentially serious complications requiring immediate evaluation (e.g. progressive weakness). To examine delayed adverse events the patients will be asked to select any of a number of the symptoms used by the list of adverse events for up to 72 hours after the procedure (the patients will be asked to bring the completed lists of the symptoms to their follow up visit in 1 month after a procedure). All patients will be seen at a follow-up appointment with their pain treating physician in the Pain Department of Tel HaShomer in 1, 2 and 3 months following the procedure. Results: The baseline characteristics of all participating patients will be collected. Numerical data will include age, height, weight, body mass index, total duration of pain. Categorical data will include sex, diagnosis, coexisting medical conditions such as diabetes and hypertension, target location, and level of the compromised nerve root(s). A comprehensive review and statistical analysis of data will be conducted at the completion of the study. Changes in pain scores, as reported by the patients via the NRS scores, will be analyzed before the procedure and at 1, 2 and 3 months postprocedure. Changes in ADL and QoL will be measured using the Roland Disability Questionnaire and the Oswestry low back pain disability scales. Both the Roland Disability Questionnaire and the Oswestry scores will be completed by the patients both before the procedure and at 1, 2 and 3 months postprocedure. Successful pain relief (responders) will be defined as either ≥50% or ≥4-point pain reduction in the NRS; functional success will be defined as either ≥40% reduction in Roland Disability Questionnaire or Oswestry Disability Index scores. Data analyses will be carried out with the help of a package of statistical programs Win Pepi (the fourth version). Categorical and continuous data comparison, Chi-squared test (Fisher's exact test where necessary) and t test will be performed. The outcome data of the patients will be measured at 4 periods of time therefore a repeated measures analysis of variance will be performed. A P value of less than 0.05 will be considered as statistically significant.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Radicular; Neuropathic, Lumbar, Lumbosacral, Low Back Pain, Back Pain With Radiation
    Keywords
    lumbar dorsal root ganglion, transforaminal epidural steroid injection, chronic lumbosacral radicular pain, pulsed radiofrequency treatment, betamethasone, dorsal root ganglion

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    120 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Celestone
    Arm Type
    Experimental
    Arm Description
    all patients of the experimental Celestone group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of Celestone® Chronodose® around each dorsal root ganglion immediately after the radiofrequency treatment has been performed.
    Arm Title
    Control
    Arm Type
    Other
    Arm Description
    all patients of the control group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of normal saline around each dorsal root ganglion immediately after the radiofrequency treatment will be performed.
    Intervention Type
    Drug
    Intervention Name(s)
    Celestone
    Intervention Description
    all of the patients of the experimental Celestone group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of Celestone® Chronodose® around each dorsal root ganglion immediately after the radiofrequency treatment has been performed
    Intervention Type
    Procedure
    Intervention Name(s)
    pulsed radiofrequency treatment
    Intervention Description
    all of the patients who will participate in the study will receive pulsed radiofrequency treatment adjacent to lumbosacral dorsal root ganglion(s).
    Intervention Type
    Drug
    Intervention Name(s)
    Control
    Intervention Description
    all of the patients of the control group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of normal saline around each dorsal root ganglion immediately after the radiofrequency treatment will be performed.
    Primary Outcome Measure Information:
    Title
    pain scores
    Description
    Changes in pain scores, as reported by the patients via the NRS scores, will be analyzed before the procedure and at 1, 2 and 3 months after the treatment
    Time Frame
    before the procedure and at 1, 2 and 3 months after the treatment
    Title
    quality of life and activities of daily living
    Description
    The potential changes in quality of life and activities of daily living will be measured by validated Roland Disability Questionnaire or Oswestry Disability Index scores
    Time Frame
    before the procedure and at 1, 2 and 3 months after the treatment
    Secondary Outcome Measure Information:
    Title
    adverse events
    Time Frame
    immediately and for up to 72 hours after the treatment

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: men and women age ≥18 years old, pain intensity≥4 out of 10 on the numerical rating scale (NRS), chronic lumbosacral radicular pain lasting ≥12 weeks, dominant leg pain with less intense back pain, the previous failure of conservative management such as physiotherapy, exercise therapy, or analgesic medications. segmental pain of a radicular nature originating from the lumbar segments and with a shooting or lancinating quality corresponding to a dermatome suggestive of the involved nerve root. availability of computed tomography/magnetic resonance imaging findings of pathology concordant with the side and level of their clinical features. Exclusion Criteria: patient refusal to participate in the study, age <18 years, pregnant or nursing pain <4-points on NRS, acute pain of onset lasting<12 weeks, progressive motor weakness in the affected leg, allergies to local anesthetics, contrast dyes or steroids significant anatomic deformity (either congenital or acquired) making it difficult to access the foramen as evidenced by computed tomography/magnetic resonance imaging presence of cancer accounting for back pain patients with platelet dysfunction, bleeding disorder or continuing anticoagulant treatment steroid injection within the previous 12 weeks, systemic infection, injection site infection, unstable medical or psychiatric condition
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Vadim Tashlikov, M.D.
    Phone
    0504820159
    Ext
    +972
    Email
    vtashl@gmail.com
    First Name & Middle Initial & Last Name or Official Title & Degree
    Dmitry Shklovsky, M.D.
    Phone
    0524774479
    Ext
    +972
    Email
    dm86sh@gmail.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Vadim Tashlikov, M.D.
    Organizational Affiliation
    Sheba Medical Center Hospital, Israel
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    195255
    Citation
    Howe JF, Loeser JD, Calvin WH. Mechanosensitivity of dorsal root ganglia and chronically injured axons: a physiological basis for the radicular pain of nerve root compression. Pain. 1977 Feb;3(1):25-41. doi: 10.1016/0304-3959(77)90033-1.
    Results Reference
    background
    PubMed Identifier
    12098606
    Citation
    Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, Felix R, Riess H. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol. 2002 Jul;43(1):33-56. doi: 10.1016/s1040-8428(01)00179-2.
    Results Reference
    background
    PubMed Identifier
    25530347
    Citation
    Koh W, Choi SS, Karm MH, Suh JH, Leem JG, Lee JD, Kim YK, Shin J. Treatment of chronic lumbosacral radicular pain using adjuvant pulsed radiofrequency: a randomized controlled study. Pain Med. 2015 Mar;16(3):432-41. doi: 10.1111/pme.12624. Epub 2014 Dec 19. Erratum In: Pain Med. 2015 Oct;16(10):2048.
    Results Reference
    background
    PubMed Identifier
    21812907
    Citation
    Van Boxem K, van Bilsen J, de Meij N, Herrler A, Kessels F, Van Zundert J, van Kleef M. Pulsed radiofrequency treatment adjacent to the lumbar dorsal root ganglion for the management of lumbosacral radicular syndrome: a clinical audit. Pain Med. 2011 Sep;12(9):1322-30. doi: 10.1111/j.1526-4637.2011.01202.x. Epub 2011 Aug 3.
    Results Reference
    background
    PubMed Identifier
    8621256
    Citation
    Yonezawa M, Otsuka T, Matsui N, Tsuji H, Kato KH, Moriyama A, Kato T. Hyperthermia induces apoptosis in malignant fibrous histiocytoma cells in vitro. Int J Cancer. 1996 May 3;66(3):347-51. doi: 10.1002/(SICI)1097-0215(19960503)66:33.0.CO;2-8.
    Results Reference
    background
    PubMed Identifier
    21116663
    Citation
    Chua NH, Vissers KC, Sluijter ME. Pulsed radiofrequency treatment in interventional pain management: mechanisms and potential indications-a review. Acta Neurochir (Wien). 2011 Apr;153(4):763-71. doi: 10.1007/s00701-010-0881-5. Epub 2010 Nov 30.
    Results Reference
    background
    PubMed Identifier
    18539061
    Citation
    Hagiwara S, Iwasaka H, Takeshima N, Noguchi T. Mechanisms of analgesic action of pulsed radiofrequency on adjuvant-induced pain in the rat: roles of descending adrenergic and serotonergic systems. Eur J Pain. 2009 Mar;13(3):249-52. doi: 10.1016/j.ejpain.2008.04.013. Epub 2008 Jun 6.
    Results Reference
    background
    PubMed Identifier
    22546701
    Citation
    Laboureyras E, Rivat C, Cahana A, Richebe P. Pulsed radiofrequency enhances morphine analgesia in neuropathic rats. Neuroreport. 2012 Jun 20;23(9):535-9. doi: 10.1097/WNR.0b013e3283541179.
    Results Reference
    background
    PubMed Identifier
    24077210
    Citation
    Vallejo R, Tilley DM, Williams J, Labak S, Aliaga L, Benyamin RM. Pulsed radiofrequency modulates pain regulatory gene expression along the nociceptive pathway. Pain Physician. 2013 Sep-Oct;16(5):E601-13.
    Results Reference
    background
    PubMed Identifier
    22643086
    Citation
    Wu B, Ni J, Zhang C, Fu P, Yue J, Yang L. Changes in spinal cord met-enkephalin levels and mechanical threshold values of pain after pulsed radio frequency in a spared nerve injury rat model. Neurol Res. 2012 May;34(4):408-14. doi: 10.1179/1743132812Y.0000000026.
    Results Reference
    background
    Citation
    11. Sluijter ME, Cosman ER, Rittman IIWB, van Kleef M. The effects of pulsed radiofrequency field applied to the dorsal root ganglion-A preliminary report. The Pain Clinic 1998;11(2):109-17.
    Results Reference
    background
    PubMed Identifier
    10204759
    Citation
    Munglani R. The longer term effect of pulsed radiofrequency for neuropathic pain. Pain. 1999 Mar;80(1-2):437-9. doi: 10.1016/s0304-3959(98)00183-3.
    Results Reference
    background
    PubMed Identifier
    17177757
    Citation
    Teixeira A, Grandinson M, Sluijter ME. Pulsed radiofrequency for radicular pain due to a herniated intervertebral disc--an initial report. Pain Pract. 2005 Jun;5(2):111-5. doi: 10.1111/j.1533-2500.2005.05207.x.
    Results Reference
    background
    PubMed Identifier
    17305674
    Citation
    Abejon D, Garcia-del-Valle S, Fuentes ML, Gomez-Arnau JI, Reig E, van Zundert J. Pulsed radiofrequency in lumbar radicular pain: clinical effects in various etiological groups. Pain Pract. 2007 Mar;7(1):21-6. doi: 10.1111/j.1533-2500.2007.00105.x.
    Results Reference
    background
    PubMed Identifier
    18354708
    Citation
    Simopoulos TT, Kraemer J, Nagda JV, Aner M, Bajwa ZH. Response to pulsed and continuous radiofrequency lesioning of the dorsal root ganglion and segmental nerves in patients with chronic lumbar radicular pain. Pain Physician. 2008 Mar-Apr;11(2):137-44.
    Results Reference
    background
    PubMed Identifier
    18207554
    Citation
    Chao SC, Lee HT, Kao TH, Yang MY, Tsuei YS, Shen CC, Tsou HK. Percutaneous pulsed radiofrequency in the treatment of cervical and lumbar radicular pain. Surg Neurol. 2008 Jul;70(1):59-65; discussion 65. doi: 10.1016/j.surneu.2007.05.046. Epub 2008 Jan 22.
    Results Reference
    background
    PubMed Identifier
    16921454
    Citation
    Shabat S, Pevsner Y, Folman Y, Gepstein R. Pulsed radiofrequency in the treatment of patients with chronic neuropathic spinal pain. Minim Invasive Neurosurg. 2006 Jun;49(3):147-9. doi: 10.1055/s-2006-944238.
    Results Reference
    background
    PubMed Identifier
    15844456
    Citation
    Pevzner E, David R, Leitner Y, Pekarsky I, Folman Y, Gepstein R. [Pulsed radiofrequency treatment of severe radicular pain]. Harefuah. 2005 Mar;144(3):178-80, 231. Hebrew.
    Results Reference
    background
    PubMed Identifier
    26273016
    Citation
    Leung SM, Chau WW, Law SW, Fung KY. Clinical value of transforaminal epidural steroid injection in lumbar radiculopathy. Hong Kong Med J. 2015 Oct;21(5):394-400. doi: 10.12809/hkmj144310. Epub 2015 Aug 14.
    Results Reference
    background
    PubMed Identifier
    25668413
    Citation
    Bateman BT, Brenner GJ. An important step forward in the safe use of epidural steroid injections. Anesthesiology. 2015 May;122(5):964-6. doi: 10.1097/ALN.0000000000000615. No abstract available.
    Results Reference
    background
    PubMed Identifier
    25668411
    Citation
    Rathmell JP, Benzon HT, Dreyfuss P, Huntoon M, Wallace M, Baker R, Riew KD, Rosenquist RW, Aprill C, Rost NS, Buvanendran A, Kreiner DS, Bogduk N, Fourney DR, Fraifeld E, Horn S, Stone J, Vorenkamp K, Lawler G, Summers J, Kloth D, O'Brien D Jr, Tutton S. Safeguards to prevent neurologic complications after epidural steroid injections: consensus opinions from a multidisciplinary working group and national organizations. Anesthesiology. 2015 May;122(5):974-84. doi: 10.1097/ALN.0000000000000614.
    Results Reference
    background
    PubMed Identifier
    26444582
    Citation
    Racoosin JA, Seymour SM, Cascio L, Gill R. Serious Neurologic Events after Epidural Glucocorticoid Injection--The FDA's Risk Assessment. N Engl J Med. 2015 Dec 10;373(24):2299-301. doi: 10.1056/NEJMp1511754. Epub 2015 Oct 7. No abstract available.
    Results Reference
    background
    PubMed Identifier
    25586082
    Citation
    Kennedy DJ, Levin J, Rosenquist R, Singh V, Smith C, Stojanovic MP, Vorobeychik Y. Epidural Steroid Injections are Safe and Effective: Multisociety Letter in Support of the Safety and Effectiveness of Epidural Steroid Injections. Pain Med. 2015 May;16(5):833-8. doi: 10.1111/pme.12667. Epub 2015 Jan 13.
    Results Reference
    background
    Citation
    Bhargava A, DePalma MJ, Ludwig S, Gelb D, Slipman CW. Injection therapy for lumbar radiculopathy.Curr OpinOrthop 2005;16:152-7
    Results Reference
    background
    PubMed Identifier
    17256030
    Citation
    Abdi S, Datta S, Trescot AM, Schultz DM, Adlaka R, Atluri SL, Smith HS, Manchikanti L. Epidural steroids in the management of chronic spinal pain: a systematic review. Pain Physician. 2007 Jan;10(1):185-212.
    Results Reference
    background

    Learn more about this trial

    Transforaminal Epidural Steroid Injection With Pulsed Radiofrequency for Chronic Lumbosacral Radicular Pain Management

    We'll reach out to this number within 24 hrs